NASDAQ:RDNT - RadNet Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.72 -0.38 (-2.70 %) (As of 11/13/2018 10:55 AM ET)Previous Close$14.10Today's Range$13.63 - $14.2352-Week Range$9.50 - $16.54Volume2,579 shsAverage Volume238,221 shsMarket Capitalization$647.02 millionP/E Ratio47.31Dividend YieldN/ABeta0.36 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California. Receive RDNT News and Ratings via Email Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDNT Previous Symbol CUSIPN/A Webwww.radnet.com Phone310-478-7808 Debt Debt-to-Equity Ratio4.49 Current Ratio1.06 Quick Ratio1.06 Price-To-Earnings Trailing P/E Ratio47.31 Forward P/E Ratio38.11 P/E Growth4.72 Sales & Book Value Annual Sales$922.19 million Price / Sales0.72 Cash Flow$1.8029 per share Price / Cash7.61 Book Value$1.47 per share Price / Book9.33 Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$50,000.00 Net Margins-0.44% Return on Equity15.23% Return on Assets1.75% Miscellaneous Employees7,440 Outstanding Shares48,280,000Market Cap$647.02 million OptionableOptionable RadNet (NASDAQ:RDNT) Frequently Asked Questions What is RadNet's stock symbol? RadNet trades on the NASDAQ under the ticker symbol "RDNT." How were RadNet's earnings last quarter? RadNet Inc. (NASDAQ:RDNT) issued its earnings results on Friday, November, 9th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by $0.05. The medical research company had revenue of $242.10 million for the quarter, compared to the consensus estimate of $240.07 million. RadNet had a negative net margin of 0.44% and a positive return on equity of 15.23%. The company's revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.12 EPS. View RadNet's Earnings History. When is RadNet's next earnings date? RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for RadNet. What guidance has RadNet issued on next quarter's earnings? RadNet updated its FY 2018 earnings guidance on Friday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $945-970 million, compared to the consensus revenue estimate of $968.47 million. What price target have analysts set for RDNT? 3 Wall Street analysts have issued twelve-month price targets for RadNet's stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate RadNet's share price to reach $14.6667 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View Analyst Price Targets for RadNet. What is the consensus analysts' recommendation for RadNet? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for RadNet. Has RadNet been receiving favorable news coverage? Media stories about RDNT stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. RadNet earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days. Who are some of RadNet's key competitors? Some companies that are related to RadNet include Natera (NTRA), CareDx (CDNA), InVitae (NVTA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), CBA Florida (CBAI), OpGen (OPGN) and Aeon Global Health (AGHC). Who are RadNet's key executives? RadNet's management team includes the folowing people: Mr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 72)Mr. Mark D. Stolper, Exec. VP & CFO (Age 47)Mr. Jeffrey L. Linden, Exec. VP & Gen. Counsel (Age 75)Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 62)Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 57) Who are RadNet's major shareholders? RadNet's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.40%), FMR LLC (4.36%), Dimensional Fund Advisors LP (3.25%), Cheyne Capital Management UK LLP (1.60%), Beck Mack & Oliver LLC (1.07%) and JPMorgan Chase & Co. (1.00%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet. Which institutional investors are selling RadNet stock? RDNT stock was sold by a variety of institutional investors in the last quarter, including Beck Mack & Oliver LLC, Acadian Asset Management LLC, ClariVest Asset Management LLC, Credit Suisse AG, EAM Global Investors LLC, EAM Investors LLC, Miracle Mile Advisors LLC and Strs Ohio. Company insiders that have sold RadNet company stock in the last year include Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet. Which institutional investors are buying RadNet stock? RDNT stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Cheyne Capital Management UK LLP, Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A., Alliancebernstein L.P., JPMorgan Chase & Co. and WINTON GROUP Ltd. View Insider Buying and Selling for RadNet. How do I buy shares of RadNet? Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is RadNet's stock price today? One share of RDNT stock can currently be purchased for approximately $13.72. How big of a company is RadNet? RadNet has a market capitalization of $647.02 million and generates $922.19 million in revenue each year. The medical research company earns $50,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 7,440 workers across the globe. What is RadNet's official website? The official website for RadNet is http://www.radnet.com. How can I contact RadNet? RadNet's mailing address is 1510 COTNER AVENUE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected] MarketBeat Community Rating for RadNet (NASDAQ RDNT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 230 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 430MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: Why does a company issue an IPO?